Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man

J Hypertens. 2001 Nov;19(11):2001-9. doi: 10.1097/00004872-200111000-00010.

Abstract

Background: It has been clearly demonstrated that angiotensin(1-7) potentiates the vasodilating effect of bradykinin in isolated vessels of animals.

Objective: To investigate the interaction between angiotensin(1-7) Ang(1-7) and bradykinin in human forearm resistant vessels of normotensive healthy men in vivo, by the measurement of forearm blood flow using venous occlusion, strain-gauge plethysmography with intra-arterial infusions of peptides in a placebo-controlled, double-blind, cross-over design.

Methods: In eight men, bradykinin was infused intra-arterially twice; placebo, Ang(1-7), or angiotensin II was co-infused with the second infusion. The effect of inhibition of nitric oxide synthase on the interaction between Ang(1-7) and bradykinin was also tested in eight other individuals. The effects of Ang(1-7) were analyzed by analysis of variance (ANOVA) and by the ratios of individually derived areas under the dose-response curves (AUC) of bradykinin, adjusted for changes in the AUCs by repeated infusions of bradykinin with placebo.

Results: Ang(1-7) (1000 pmol/min) significantly potentiated the vasodilating effect of bradykinin compared with the effect of saline (P = 0.0471, ANOVA) and in a dose-dependent manner (adjusted AUC ratio [95% confidence interval (CI)] 2.75 (1.72 to 3.78) with 1000 pmol/min, 1.62 (1.31 to 1.93) with 100 pmol/min, and 0.98 (0.80, to 1.09) with 10 pmol/min). This effect was completely abolished by co-infusion of NG-monomethyl-l-arginine [AUC ratio 0.98 (0.90 to 1.04)]. Ang(1-7) did not affect the vasodilating effects of either acetylcholine or sodium nitroprusside.

Conclusions: Ang(1-7) potentiates the vasodilating effect of bradykinin, possibly through a mechanism(s) involving nitric oxide release, in human forearm resistance vessels.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiotensin I / administration & dosage
  • Angiotensin I / pharmacology*
  • Angiotensin II / pharmacology
  • Bradykinin / administration & dosage
  • Bradykinin / pharmacology*
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Synergism
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Male
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology*
  • Reference Values
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation / drug effects*
  • omega-N-Methylarginine / pharmacology

Substances

  • Enzyme Inhibitors
  • Peptide Fragments
  • Vasoconstrictor Agents
  • Angiotensin II
  • omega-N-Methylarginine
  • Angiotensin I
  • angiotensin I (1-7)
  • Bradykinin